Alto Neuroscience 8-K: Agreements, Sales, and Other Events

TL;DR

Alto Neuroscience 8-K: Material agreements entered & terminated, unregistered equity sales. Keep an eye on this.

AI Summary

Alto Neuroscience, Inc. filed an 8-K on October 20, 2025, reporting on events as of October 19, 2025. The filing indicates the entry into and termination of material definitive agreements, unregistered sales of equity securities, and other events, including financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Mountain View, California.

Why It Matters

This 8-K filing by Alto Neuroscience signals significant corporate actions, including potential changes in agreements and equity transactions, which could impact its operational and financial standing.

Risk Assessment

Risk Level: medium — The filing mentions termination of material definitive agreements and unregistered sales of equity securities, which can indicate potential financial or strategic shifts that warrant closer examination.

Key Players & Entities

• Alto Neuroscience, Inc. (company) — Registrant
• October 19, 2025 (date) — Earliest event reported
• October 20, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 650 Castro St, Suite 450, Mountain View, CA 94041 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share ANRO New York S
• $5.914 — hase price per share of Common Stock is $5.914 per share (the " Purchase Price ") and
• $50.0 million — ceiving gross proceeds of approximately $50.0 million from the Private Placement, before dedu
• $0 — ants have a per share exercise price of $0.0001, subject to proportional adjustmen
• $75 million — ng an aggregate offering price of up to $75 million. On October 20, 2025, the Company deliv
• $50 Million — e entitled "Alto Neuroscience Announces $50 Million Private Placement Financing." The full

Filing Documents

• tm2529007d1_8k.htm (8-K) — 40KB
• tm2529007d1_ex4-1.htm (EX-4.1) — 87KB
• tm2529007d1_ex10-1.htm (EX-10.1) — 213KB
• tm2529007d1_ex10-2.htm (EX-10.2) — 94KB
• tm2529007d1_ex99-1.htm (EX-99.1) — 14KB
• tm2529007d1_ex99-2.htm (EX-99.2) — 16KB
• tm2529007_ex99-1img001.jpg (GRAPHIC) — 17KB
• 0001104659-25-100801.txt ( ) — 768KB
• anro-20251019.xsd (EX-101.SCH) — 3KB
• anro-20251019_lab.xml (EX-101.LAB) — 33KB
• anro-20251019_pre.xml (EX-101.PRE) — 22KB
• tm2529007d1_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry Into A Material Definitive Agreement. Private Placement of Common Stock and Warrants On October 19, 2025, Alto Neuroscience, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain institutional and other accredited investors (the " Purchasers "), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the " Private Placement ") (i) 3,832,263 shares (the " Shares ") of the Company's common stock, par value $0.0001 (" Common Stock "), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 4,622,251 shares of Common Stock (the " Pre-Funded Warrants ") in lieu of Shares. The purchase price per share of Common Stock is $5.914 per share (the " Purchase Price ") and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant. The Company anticipates receiving gross proceeds of approximately $50.0 million from the Private Placement, before deducting offering expenses payable by the Company. The Pre-Funded Warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events. The Pre-Funded Warrants will not expire until exercised in full. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof immediately following such exercise would exceed a specified beneficial ownership limitation; provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61 days' notice to the Company, but not to any percentage in excess of 19.9%. Under the terms of the Purchase Agreement, the Company has agreed to prepare and file, within 45 days after the Closing (the " Filing Deadline "), one or more registration statements with the Securities and Exchange Commission (the " SEC ") to register for res

02

Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, on February 3, 2025, the Company entered into a Sales Agreement (the " Sales Agreement ") with Leerink Partners LLC (the " Agent "), pursuant to which the Company from time to time may offer and sell shares of its common stock through or to the Agent having an aggregate offering price of up to $75 million. On October 20, 2025, the Company delivered written notice to the Agent to terminate the Sales Agreement, effective October 30, 2025 in accordance with the terms of the Sales Agreement. The Company had not sold any shares of common stock under the Sales Agreement prior to termination. The description of the Sales Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 3, 2025.

02

Item 3.02 Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under Item 1.01 of this report is incorporated by reference under this Item 3.02. The securities described above under Item 1.01 have not been registered under the Securities Act of 1933, as amended (the " Securities Act "). Based in part upon the representations of the Purchasers in the Purchase Agreement, the Company relied on the exemption afforded by Regulation D under the Securities Act, and corresponding provisions of state securities or "blue sky" laws. Each of the Purchasers has represented that it is an "accredited investor" as defined in Regulation D of the Securities Act and that it is acquiring the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, and appropriate legends will be affixed to the securities. The sale of the securities did not involve a public offering and was made without general solicitation or general advertising. Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy any securities of the Company.

01

Item 8.01 Other Events. On October 20, 2025, the Company issued a press release entitled "Alto Neuroscience Announces $50 Million Private Placement Financing." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company concurrently issued a press release entitled "Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting." The full text of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1 Form of Securities Purchase Agreement, dated October 19, 2025, by and among Alto Neuroscience, Inc. and the Purchasers. 10.2 Form of Registration Rights Agreement, dated October 19, 2025, by and among Alto Neuroscience, Inc. and the Purchasers. 99.1 Press Release of Alto Neuroscience, Inc. 99.2 Press Release of Alto Neuroscience, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: October 20, 2025 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR